Tag: Zhu Ke
Firms act on medtech maker Cofoe Medical’s HKD1.06bn IPO
Cofoe Medical Technology lists on the HKEX main board becoming the first home medical equipment maker to achieve a dual listing
Firms assist Eastroc Beverage on HKD10.1bn HKEX IPO
Health drinks producer Eastroc Beverage has debuted on the HKEX, raising HKD10.1 billion. HSF Kramer, DeHeng , Jia Yuan and O’Melveny advised on the listing
Four law firms counsel on HKD905m Laopu Gold Hong Kong IPO
O’Melveny, Global Law Office, Linklaters and Haiwen & Partners have clinched roles in Chinese jewellery brand Laopu Gold’s listing on the HKEX
Cancer drug firm Adlai Nortye raises USD97.5m in Nasdaq IPO
O’Melveny, Han Kun Law Offices, Maples Group, Latham & Watkins and Zhong Lun Law Firm advised on cancer drug developer Adlai Nortye’s Nasdaq debut
Fourth Paradigm clinches HKD1.02bn IPO on fourth endeavour
China’s AI unicorn Fourth Paradigm, after three previous attempts, has successfully listed on the HKEX raising HKD1.02 billion (USD130 million)
Luzhu Biotechnology launches HKD341m IPO via chapter 18A
Luzhu Biotechnology debuted on the HKEX through chapter 18A, the first biotech company without any revenue or profits to be listed this year, raising USD43.45 million
O’Melveny acts on Acotec Scientific’s partial offering
O’Melveny advised China’s medical technology company, Acotec Scientific Holdings, on the voluntary partial offer for a majority stake of up to 65% by US-listed Boston Scientific Group
